A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders
Te. Witzig et al., A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders, LEUK LYMPH, 38(3-4), 2000, pp. 345
Malignant plasma cells can be detected in the blood of patients with multip
le myeloma (MM) using flow cytometry (FC), immunofluorescence microscopy (I
M), or a variety of molecular techniques. Increased numbers of light chain-
restricted blood plasma cells as detected by IM is associated with a diagno
sis of overt MM and a decreased overall survival. The IM technique is time
consuming; therefore, a prospective study was designed to test whether CD38
CD45 FC could simplify the procedure. Blood samples from 769 patients with
plasma cell proliferative disorders were studied prospectively by FC and I
M over a one-year period. The FC technique was performed on 1 ml of whole b
lood after ammonium chloride red blood cell lysis and utilized anti-CD38PE
and anti-CD45PerCP. The number of CD38+ 45- events were enumerated and comp
ared to the number of light chain-restricted plasma cells detected by the s
tandard IM technique. In 46% (353/769) of cases greater than or equal to 1
CD38+ CD45- events were detected by FC whereas IM was positive for light ch
ain restricted plasma cells in 33%; there was concordance between FC and IM
in 73% of cases. In 20% of cases FC was positive and IM was negative; howe
ver, in 7% of cases FC was negative yet light chain-restricted plasma cells
were detected by IM. FC was positive: in 88% (134/153) of cases where the
IM technique showed a high number of circulating plasma cells. This study d
emonstrates that two-color CD38/45 FC identifies most cases with a high IM
result and reduces the workload in the clinical laboratory. The prognostic
implications of a positive FC screen but a negative IM will require long-te
rm patient follow-up.